BioPeak, an emerging AI-first biomarker discovery startup founded in 2024 by a team of computational biologists and clinicians from IITs and AIIMS, has successfully closed a $2.7 million seed funding round led by Nikhil Kamath’s NK Squared. The round, finalised in mid-January 2026, also saw participation from a group of high-profile angel investors and healthtech focused early stage funds, reflecting strong belief in BioPeak’s potential to transform how biomarkers are discovered and translated into clinical practice.

At its core, BioPeak’s platform uses advanced machine learning and deep learning models to integrate multi-omics datasets genomics, proteomics, metabolomics, and clinical phenotypes from large cohorts of Indian patients. By identifying novel biomarker signatures with high predictive power, the company aims to enable earlier detection of chronic diseases (diabetes, cardiovascular conditions, cancers), more precise risk stratification, and personalised treatment selection. Unlike traditional biomarker discovery that can take years and cost millions, BioPeak’s AI-driven approach compresses timelines and reduces costs dramatically while prioritising Indian population specific patterns often underrepresented in global datasets.

The funding will be deployed to:

• Scale computational infrastructure and expand the proprietary multi-omics dataset
• Grow the engineering, bioinformatics, and clinical validation teams
• Initiate prospective clinical studies with partner hospitals to validate biomarker panels
• Build integrations with diagnostic labs and hospital EHRs for real-world deployment
• Strengthen IP portfolio and pursue regulatory clearances (CDSCO, ICMR) for diagnostic use

Nikhil Kamath, co-founder of Zerodha and NK Squared, commented: “Biomarker discovery has been bottlenecked by slow, expensive processes. BioPeak’s AI-first approach changes that delivering faster, more accurate insights grounded in Indian data. We’re excited to back a team that can make precision medicine truly accessible and scalable in India and beyond.”

BioPeak Co-founder and CEO Dr. Arjun Rao added: “This funding validates our mission to build India centric biomarker intelligence that drives earlier detection and better outcomes. With NK Squared’s support, we can move rapidly from research to real-world impact starting with high-burden conditions like diabetes and cardiovascular disease.”

The investment comes at a pivotal time for India’s biotech and diagnostics sector, where rising chronic disease prevalence, increasing insurance penetration, and government emphasis on preventive health are creating strong tailwinds. BioPeak’s focus on population specific data also addresses a critical gap in global biomarker research, where most models are trained on Western cohorts and perform sub-optimally on Indian populations.

The company has already established early partnerships with diagnostic chains and academic medical centres for validation studies, with first commercial biomarker panels targeted for launch in late 2026 or early 2027.